These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 36771784)
1. Study of Formulation and Process Variables for Optimization of Piroxicam Nanosuspension Using 3 Alhamhoom Y; Honmane SM; Hani U; Osmani RAM; Kandasamy G; Vasudevan R; Paramshetti S; R Dudhal R; K Kengar N; Charde MS Polymers (Basel); 2023 Jan; 15(3):. PubMed ID: 36771784 [TBL] [Abstract][Full Text] [Related]
2. Formulation strategy and evaluation of nanocrystal piroxicam orally disintegrating tablets manufacturing by freeze-drying. Lai F; Pini E; Corrias F; Perricci J; Manconi M; Fadda AM; Sinico C Int J Pharm; 2014 Jun; 467(1-2):27-33. PubMed ID: 24680963 [TBL] [Abstract][Full Text] [Related]
3. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology. Gajera BY; Shah DA; Dave RH Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724 [TBL] [Abstract][Full Text] [Related]
4. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. Nagaraj K; Narendar D; Kishan V Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908 [TBL] [Abstract][Full Text] [Related]
5. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes. Patel PJ; Gajera BY; Dave RH Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778 [TBL] [Abstract][Full Text] [Related]
6. Preparation, Characterization, and Evaluation of Breviscapine Nanosuspension and Its Freeze-Dried Powder. Zhang T; Li X; Xu J; Shao J; Ding M; Shi S Pharmaceutics; 2022 Apr; 14(5):. PubMed ID: 35631508 [TBL] [Abstract][Full Text] [Related]
7. Preparation of Piroxicam nanosuspensions by high pressure homogenization and evaluation of improved bioavailability. Aksoy OA; Zanbak Çotaoğlu M; Fatsa T; Topal GR; Eşim Ö; Göksel BA; Hoşbul T; Özkan CK; Savaşer A; Özkan Y Drug Dev Ind Pharm; 2023 Dec; 49(12):715-722. PubMed ID: 38087641 [TBL] [Abstract][Full Text] [Related]
8. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations. Sawant KK; Patel MH; Patel K Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349 [TBL] [Abstract][Full Text] [Related]
9. Enhancing Betulinic Acid Dissolution Rate and Improving Antitumor Activity via Nanosuspension Constructed by Anti-Solvent Technique. Li S; Zhang J; Fang Y; Yi J; Lu Z; Chen Y; Guo B Drug Des Devel Ther; 2020; 14():243-256. PubMed ID: 32021108 [TBL] [Abstract][Full Text] [Related]
10. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability. Jain S; Reddy VA; Arora S; Patel K Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488 [TBL] [Abstract][Full Text] [Related]
11. 24 Factorial Design Formulation Optimization and In vitro Characterization of Desloratadine Nanosuspension Prepared Using Antisolvent Precipitation. El-Sebaiy MT; Alyami MH; Alyami HS; Kamal MA; Eissa N; Balata G; El-Nahas H Curr Drug Deliv; 2024 Jun; ():. PubMed ID: 38867526 [TBL] [Abstract][Full Text] [Related]
12. Dermal flurbiprofen nanosuspensions: Optimization with design of experiment approach and in vitro evaluation. Oktay AN; Karakucuk A; Ilbasmis-Tamer S; Celebi N Eur J Pharm Sci; 2018 Sep; 122():254-263. PubMed ID: 29981401 [TBL] [Abstract][Full Text] [Related]
13. Nanosuspension of efavirenz for improved oral bioavailability: formulation optimization, in vitro, in situ and in vivo evaluation. Patel GV; Patel VB; Pathak A; Rajput SJ Drug Dev Ind Pharm; 2014 Jan; 40(1):80-91. PubMed ID: 23323843 [TBL] [Abstract][Full Text] [Related]
14. Isoliquiritigenin Nanosuspension Enhances Cytostatic Effects in A549 Lung Cancer Cells. Qiao F; Zhao Y; Mai Y; Guo J; Dong L; Zhang W; Yang J Planta Med; 2020 May; 86(8):538-547. PubMed ID: 32294789 [TBL] [Abstract][Full Text] [Related]
15. Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach. Mohapatra PK; Srivastava R; Varshney KK; Babu SH Anticancer Agents Med Chem; 2022; 22(10):1984-2001. PubMed ID: 34353274 [TBL] [Abstract][Full Text] [Related]
16. Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation. Nakarani M; Misra AK; Patel JK; Vaghani SS Daru; 2010; 18(2):84-90. PubMed ID: 22615599 [TBL] [Abstract][Full Text] [Related]
17. Preparation of finasteride capsules-loaded drug nanoparticles: formulation, optimization, in vitro, and pharmacokinetic evaluation. Ahmed TA Int J Nanomedicine; 2016; 11():515-27. PubMed ID: 26893559 [TBL] [Abstract][Full Text] [Related]
18. Application of Central Composite Design in Optimization of Valsartan Nanosuspension to Enhance its Solubility and Stability. Vuppalapati L; Cherukuri S; Neeli V; Yeragamreddy PR; Kesavan BR Curr Drug Deliv; 2016; 13(1):143-57. PubMed ID: 26205900 [TBL] [Abstract][Full Text] [Related]
19. Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. Lai F; Pini E; Angioni G; Manca ML; Perricci J; Sinico C; Fadda AM Eur J Pharm Biopharm; 2011 Nov; 79(3):552-8. PubMed ID: 21820052 [TBL] [Abstract][Full Text] [Related]
20. Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Dodiya S; Chavhan S; Korde A; Sawant KK Drug Dev Ind Pharm; 2013 May; 39(5):733-43. PubMed ID: 22690834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]